Literature DB >> 1398969

Rapid generation of specific protective immunity to Francisella tularensis.

K L Elkins1, D A Leiby, R K Winegar, C A Nacy, A H Fortier.   

Abstract

Mice inoculated either subcutaneously (s.c.) or intradermally (i.d.) with a sublethal dose of Francisella tularensis LVS are immune to a lethal intraperitoneal (i.p.) or intravenous (i.v.) challenge of LVS. Here, we show that this immunity developed quite rapidly: mice given a sublethal dose of live LVS s.c. or i.d. (but not i.v.) withstood lethal i.p., i.v., or i.d. challenge as early as 2 days after the initial inoculation, despite the presence of bacterial burdens already in tissues. The magnitude of this early protection was quite impressive. The i.p. 50% lethal dose (LD50) in naive C3H/HeN mice was only 2 bacteria, while the i.p. LD50 in mice given 10(4) LVS i.d. 3 days previously was 3 x 10(6) bacteria. Similarly, the i.v. LD50 in C3H/HeN mice shifted from 3 x 10(2) in naive mice to 5 x 10(6) in primed mice within 3 days after i.d. LVS infection. Comparable changes in the i.p. and i.v. LD50 were observed in C57BL/6J mice. This rapid generation of protective immunity was specific for LVS, in that mice given a sublethal i.d. inoculation of LVS did not survive a lethal challenge with either Salmonella typhimurium W118 or Escherichia coli O118 BORT at any time, nor could mice given sublethal doses of S. typhimurium, E. coli, or Mycobacterium bovis BCG survive lethal doses of LVS. Although an increase in the mean time to death from S. typhimurium infection was noted when mice were given a sublethal i.d. dose of LVS 4 to 14 days earlier, no overall increase in protection or change in the S. typhimurium LD50 was observed. Thus, sublethal infection with LVS at skin sites induced rapid and specific protective immunity.

Entities:  

Mesh:

Year:  1992        PMID: 1398969      PMCID: PMC258204          DOI: 10.1128/iai.60.11.4571-4577.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Mycobacteria-reactive Lyt-2+ T cell lines.

Authors:  G De Libero; I Flesch; S H Kaufmann
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

2.  In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG.

Authors:  E Kuramoto; S Toizumi; S Shimada; T Tokunaga
Journal:  Microbiol Immunol       Date:  1989       Impact factor: 1.955

3.  Roles of interferon and cellular adhesion molecules in bacterial activation of human natural killer cells.

Authors:  R A Lindemann
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

Review 4.  Cytokine modulation of keratinocyte cytokines.

Authors:  J Ansel; P Perry; J Brown; D Damm; T Phan; C Hart; T Luger; S Hefeneider
Journal:  J Invest Dermatol       Date:  1990-06       Impact factor: 8.551

Review 5.  The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses.

Authors:  T S Kupper
Journal:  J Invest Dermatol       Date:  1990-06       Impact factor: 8.551

Review 6.  Nature of protective immunity to Francisella tularensis.

Authors:  A Tärnvik
Journal:  Rev Infect Dis       Date:  1989 May-Jun

7.  Inability of recombinant interferon-gamma to activate the antibacterial activity of mouse peritoneal macrophages against Listeria monocytogenes and Salmonella typhimurium.

Authors:  J T van Dissel; J J Stikkelbroeck; B C Michel; M T van den Barselaar; P C Leijh; R van Furth
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

8.  Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis.

Authors:  E M Janis; S H Kaufmann; R H Schwartz; D M Pardoll
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

9.  Antibacterial activity of human natural killer cells.

Authors:  P Garcia-Peñarrubia; F T Koster; R O Kelley; T D McDowell; A D Bankhurst
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection.

Authors:  A S Cross; J C Sadoff; N Kelly; E Bernton; P Gemski
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  15 in total

1.  Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity.

Authors:  C M Bosio; K L Elkins
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling.

Authors:  Leah E Cole; Michelle H W Laird; Anna Seekatz; Araceli Santiago; Zhaozhao Jiang; Eileen Barry; Kari Ann Shirey; Katherine A Fitzgerald; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

3.  Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Authors:  Leah E Cole; Barbara J Mann; Kari Ann Shirey; Katharina Richard; Yang Yang; Patricia J Gearhart; Kirsty L Chesko; Rose M Viscardi; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2011-07-12       Impact factor: 4.962

Review 4.  Antibody-independent functions of B cells: a focus on cytokines.

Authors:  Ping Shen; Simon Fillatreau
Journal:  Nat Rev Immunol       Date:  2015-06-12       Impact factor: 53.106

5.  Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain.

Authors:  K L Elkins; C M Bosio; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.

Authors:  Terry H Wu; Julie A Hutt; Kristin A Garrison; Lyudmila S Berliba; Yan Zhou; C Rick Lyons
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.

Authors:  V C Dreisbach; S Cowley; K L Elkins
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

8.  Minimal requirements for murine resistance to infection with Francisella tularensis LVS.

Authors:  K L Elkins; T R Rhinehart-Jones; S J Culkin; D Yee; R K Winegar
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

9.  T-cell-independent resistance to infection and generation of immunity to Francisella tularensis.

Authors:  K L Elkins; T Rhinehart-Jones; C A Nacy; R K Winegar; A H Fortier
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Nonspecific early protective immunity in Francisella and Listeria infections can be dependent on lymphocytes.

Authors:  K L Elkins; A T MacIntyre; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.